Medtronic SG&A decreased by 0.3% to $2.96B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.8%, from $2.72B to $2.96B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
is_selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.63B | $2.55B | $2.62B | $2.56B | $2.62B | $2.57B | $2.62B | $2.62B | $2.68B | $2.61B | $2.69B | $2.67B | $2.74B | $2.66B | $2.76B | $2.72B | $3.06B | $2.81B | $2.97B | $2.96B |
| QoQ Change | — | -3.0% | +2.7% | -2.1% | +2.4% | -2.1% | +1.9% | -0.1% | +2.6% | -2.6% | +2.8% | -0.5% | +2.5% | -3.1% | +3.8% | -1.5% | +12.4% | -8.2% | +5.7% | -0.3% |
| YoY Change | — | — | — | — | -0.1% | +0.8% | +0.1% | +2.1% | +2.3% | +1.8% | +2.6% | +2.2% | +2.0% | +1.6% | +2.6% | +1.6% | +11.5% | +5.7% | +7.5% | +8.8% |